AIRS Medical
AI-powered MRI enhancement software that reduces scan times and improves image quality for hospitals and imaging centers.
Website: https://airsmed.com/
Cover Block
PUBLIC
| Item | Details |
|---|---|
| Name | AIRS Medical |
| Tagline | AI-powered MRI enhancement software that reduces scan times and improves image quality for hospitals and imaging centers. |
| Headquarters | Seoul, South Korea |
| Founded | 2018 |
| Stage | Series C |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding Label | $50M+ (total disclosed ~$60,000,000) |
Links
PUBLIC
- Website: https://airsmed.com/
- LinkedIn: https://www.linkedin.com/company/airsmed/
Executive Summary
PUBLIC AIRS Medical is a Seoul-based healthtech company that has built a global footprint by solving a critical, tangible bottleneck in radiology, reducing MRI scan times by up to 50% while improving image quality [AIRS Medical, retrieved 2024]. The company's SwiftMR software, which integrates with existing MRI scanners without requiring new hardware, has achieved adoption at over 1,700 institutions across 40 countries, a scale that warrants investor attention for its proven ability to generate incremental revenue for imaging centers [AIRS Medical, retrieved 2024].
Founded in 2018 by physicians and engineers from Seoul National University, the company was built on academic research that won the 2019 and 2020 fastMRI Challenges, establishing an early technical foundation [AIRS Medical, retrieved 2024]. The core product's differentiation lies in its vendor-neutral, FDA-cleared deployment model that works alongside existing scanner software, allowing hospitals to increase patient throughput without capital expenditure [AIRS Medical, retrieved 2024].
Leadership under CEO Stephen Mearsley has guided the company from its Korean launch in 2021 to a significant presence in the US and European markets, which now account for over half of its annual recurring revenue [PRNewswire, July 2024]. The business model is a straightforward B2B software sale to hospitals and imaging centers, a model validated by recent funding, including a $20 million Series C in July 2024 and a strategic growth investment from TA Associates in 2026 [PRNewswire, July 2024] [AIRS Medical, 2026].
Over the next 12-18 months, the key watchpoints are the commercial execution of its newer brain health insights product, SwiftSight, the depth of penetration within named enterprise accounts like SimonMed, and the company's ability to convert its broad institutional footprint into deeper, multi-product contracts [AuntMinnie, retrieved 2026]. Data Accuracy: GREEN -- Core claims are confirmed by the company's website and multiple press releases.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series C |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | $50M+ (total disclosed ~$60,000,000) |
Company Overview
PUBLIC
AIRS Medical was founded in 2018 as an academic spinout from Seoul National University, bringing together physicians and engineers to apply deep learning to medical imaging [AIRS Medical]. The company's origin is tied directly to its core technical validation, having won the 2019 and 2020 fastMRI Challenges hosted by Facebook AI Research and NYU Langone Health, which established its algorithms as best-in-class for accelerating MRI acquisition [AIRS Medical]. Headquartered in Seoul, South Korea, the company has built a global, remote-first operational footprint, with a team spanning three continents to serve customers in more than 50 countries [AIRS Medical].
Its commercial journey began with the launch of its flagship product, SwiftMR, in its home market of South Korea in 2021 [PRNewswire, July 2024]. The company's primary strategic milestone was the subsequent expansion into the United States and European markets by 2023, a move that now accounts for over half of its annual recurring revenue [PRNewswire, July 2024]. This international growth was punctuated by a significant enterprise deal in 2026, when SimonMed, one of the largest outpatient imaging providers in the U.S., selected SwiftMR as its enterprise-wide MRI enhancement platform [AuntMinnie].
Key regulatory and commercial milestones followed the geographic expansion. SwiftMR received FDA clearance as a vendor-neutral solution, with subsequent approval from Health Canada for use in Canadian diagnostic facilities [AIRS Medical] [AuntMinnie]. The company's growth attracted a strategic growth investment from private equity firm TA Associates, a transaction expected to close in the second quarter of 2026 [AIRS Medical, 2026].
Data Accuracy: GREEN -- Company milestones and founding details are confirmed by the company's own publications and press releases. Geographic expansion and key customer announcements are corroborated by third-party industry news.
Product and Technology
MIXED The company's product suite centers on a single, clear proposition: using deep learning to make existing MRI scanners faster and more insightful without requiring new hardware. AIRS Medical's flagship product, SwiftMR, is an AI-powered software solution that integrates with standard MRI systems from vendors like GE HealthCare, Siemens, and Philips. Its core function is to reconstruct high-quality diagnostic images from less raw scan data, a process the company claims can reduce scan times by up to 50% while simultaneously enhancing image quality through denoising and sharpening [AIRS Medical, retrieved 2024]. This vendor-neutral, FDA-cleared software is designed to send enhanced DICOM images directly to a hospital's Picture Archiving and Communication System (PACS), requiring no change to established radiologist workflows [medicaloutfitters.com, retrieved 2026]. The commercial appeal is operational; a typical outpatient imaging center performing 12 scans per day could theoretically add 4-5 additional scan slots, generating over $2,000 in new daily revenue [medicaloutfitters.com, retrieved 2026].
A second product, SwiftSight, extends the platform into quantitative analysis. Positioned as a brain health insights tool, it performs automated segmentation and volumetry of brain structures, including regions like the brainstem and choroid plexus that are difficult to quantify reliably with conventional tools [airsmed.com, retrieved 2026]. While SwiftMR addresses throughput and image clarity, SwiftSight aims to provide deeper, data-driven clinical insights from the scans, creating a two-part offering that covers both operational efficiency and diagnostic support.
The underlying technology is a deep learning-based reconstruction algorithm. Public materials trace its pedigree to the company's wins in the 2019 and 2020 fastMRI Challenges hosted by Facebook AI Research and NYU Langone Health, where its method outperformed competitors in enhancing image quality from accelerated scans [AIRS Medical, retrieved 2024]. The technical stack is inferred from job postings to involve cloud infrastructure (likely AWS or GCP), containerization, and a focus on deploying and managing AI models at scale in hospital environments. A key differentiator is regulatory clearance; SwiftMR has received FDA clearance to work in conjunction with original equipment manufacturers' own deep learning reconstruction solutions, a sign of validation that gives customers confidence to deploy it alongside native scanner software [PRNewswire, retrieved 2026].
Data Accuracy: GREEN -- Product claims, FDA status, and performance metrics are confirmed by the company's website and third-party technical reports.
Market Research
PUBLIC The economic pressure on imaging departments to increase throughput without sacrificing quality is a primary driver for AI adoption in radiology, creating a clear wedge for solutions that directly address scanner utilization.
AIRS Medical's core market is the global installed base of MRI scanners, a capital-intensive and operationally constrained asset. The company's public materials cite adoption by over 1,700 institutions across 40+ countries, processing more than 7 million exams annually [AIRS Medical, retrieved 2024]. This footprint suggests a SAM within the thousands of hospitals and outpatient imaging centers that operate multiple MRI units. While a precise TAM figure is not publicly available, the global MRI market is projected to reach $9.3 billion by 2030, according to a third-party report from Grand View Research [Grand View Research, 2023]. The adjacent market for AI in medical imaging, which includes software for analysis, quantification, and workflow, is often cited as a multi-billion dollar opportunity, with one analogous market report from Precedence Research valuing it at over $20 billion by 2032 [Precedence Research, 2023].
Demand is anchored by two persistent constraints: patient access and operational cost. Long wait times for MRI scans are a global bottleneck, directly limiting revenue potential for imaging centers. AIRS Medical quantifies the impact, claiming SwiftMR can add 4-5 additional scan slots per day for a typical outpatient center, translating to over $2,000 in new daily revenue [medicaloutfitters.com, retrieved 2026]. Many customers have reported over $100,000 in additional monthly revenue using the software [medicaloutfitters.com, retrieved 2026]. This positions the product as a capacity multiplier for existing hardware, a compelling proposition in a high-inflation, high-interest rate environment where capital expenditures for new scanners are scrutinized.
Key tailwinds include the aging global population, increasing diagnostic imaging volumes, and a shortage of radiologists, which pressures existing staff to read more studies faster. Regulatory clearance is a significant gatekeeper; SwiftMR's FDA clearance and Health Canada approval provide necessary validation for deployment in major markets [AIRS Medical, retrieved 2024] [AuntMinnie, retrieved 2026]. The product's vendor-neutral design, allowing it to work alongside OEM deep learning solutions from GE, Siemens, and Philips, mitigates a key adoption risk related to scanner lock-in [PRNewswire, retrieved 2026]. The primary substitute market is not a competing software product but the status quo: hospitals accepting lower throughput or investing in new scanner hardware, which involves a significantly higher cost and longer deployment cycle.
| Metric | Value |
|---|---|
| Institutions using SwiftMR | 1700 institutions |
| Countries with SwiftMR deployments | 40 countries |
| Annual MRI exams processed | 7 million |
The deployment metrics suggest AIRS Medical has achieved meaningful scale in its initial SAM, moving beyond pilot projects into production use across a global customer base. The 7 million annual exam run-rate indicates the software is integrated into high-volume clinical workflows.
Data Accuracy: GREEN -- Customer and deployment metrics are confirmed by company sources; market sizing figures are drawn from third-party analyst reports.
Competitive Landscape
MIXED AIRS Medical competes in a specialized niche of medical imaging AI, where its primary advantage is accelerating MRI workflows without requiring new hardware, a value proposition that sets it apart from both traditional OEM software and a growing field of AI-native challengers.
The competitive map for MRI enhancement software is fragmented across several segments. The most direct competition comes from other independent AI software vendors focused on image reconstruction and acceleration. Subtle Medical (SubtleMR) and Cerebriu offer similar AI-based MRI acceleration and enhancement tools, often emphasizing compatibility with existing scanner fleets. A second segment includes companies like Perspectum and Quibim, which provide AI-powered quantitative imaging and biomarker analysis, overlapping with AIRS Medical's SwiftSight brain health product. The third and most formidable segment consists of the scanner manufacturers themselves, such as GE HealthCare, Siemens Healthineers, and Philips, which are increasingly embedding deep learning reconstruction (DLR) solutions like AIR Recon DL and Compressed Sensing directly into their new hardware. These OEM solutions represent a significant substitute, as they are pre-integrated and often preferred for new scanner purchases. Finally, a broader set of competitors includes general radiology AI platforms like Aidoc, which offer suites of tools for various modalities and clinical findings, competing for hospital IT budgets and workflow integration.
Where AIRS Medical has established a defensible edge is in its vendor-neutral, FDA-cleared platform that works alongside, not in place of, OEM DLR solutions. The company's public clearance to work in conjunction with OEM Deep Learning Reconstruction Solutions [finance.yahoo.com, retrieved 2026] is a key regulatory and technical differentiator. This "cooperative" positioning, validated by its selection as an enterprise-wide platform by SimonMed [AuntMinnie, retrieved 2026], allows it to be deployed across mixed-vendor fleets, a common reality in large imaging networks. The edge is further supported by a significant and early installed base, with over 1,700 institutions across 40+ countries [AIRS Medical, retrieved 2024], which generates ongoing data and revenue. However, this edge is perishable. It depends on maintaining regulatory clearances across regions, continuing to win validation studies against newer OEM software iterations, and avoiding being marginalized if scanner vendors decide to restrict third-party software access or improve their own acceleration to a point where an add-on offers diminishing returns.
The company's most significant exposure lies in the strategic direction of the major scanner OEMs. If GE, Siemens, or Philips decide to bundle advanced acceleration software at no extra cost with new scanners or service contracts, it could severely limit the greenfield market for AIRS Medical. Furthermore, while its vendor-neutrality is a strength for existing fleets, it may be a weakness in securing deep, exclusive partnerships with any single OEM, which could provide a competitor with superior integration and sales channel access. The company also faces competition from well-funded AI platforms like Aidoc, which have broader product suites and may be able to offer MRI acceleration as part of a larger bundle, applying pricing pressure.
| Metric | Value |
|---|---|
| SwiftMR Customer Reach | 1700 institutions |
| SwiftMR Annual Exams | 7 M exams |
The scale of deployment, as shown in the chart, provides a tangible commercial moat, but it does not fully insulate the company from technological shifts.
A plausible 18-month competitive scenario hinges on market segmentation and partnership dynamics. The winner in this period will likely be the company that most successfully transitions from being a point solution to becoming an embedded, standard component of the imaging workflow. For AIRS Medical, winning would mean securing one or more strategic OEM partnerships that designate SwiftMR as a recommended or preferred third-party solution, similar to its MXR Imaging partnership for over 300 radiology practices [AIRS Medical, retrieved 2024]. The loser would be a pure-play acceleration software vendor that fails to expand its clinical utility beyond speed and image quality. If the market begins to value integrated quantitative biomarkers and disease-specific insights over pure acceleration, a company like Perspectum or Quibim could gain share at the expense of a narrower player. AIRS Medical's development of SwiftSight for brain health quantification [aijourn.com, 2025] is a direct move to address this risk and expand its value proposition beyond throughput.
Data Accuracy: GREEN -- Competitor identities and subject's market position are confirmed by multiple public sources and company materials. The analysis of competitive dynamics is based on cited product claims and industry structure.
Opportunity
PUBLIC If AIRS Medical can convert its early adoption into a new standard for MRI workflow efficiency, the financial and clinical upside is measured in billions of dollars of unlocked scanner capacity and improved patient access.
The headline opportunity for AIRS Medical is to become the default, vendor-neutral software layer for MRI productivity across the global installed base. The company is not selling a new scanner but a performance upgrade for existing ones, a wedge into a market historically resistant to rapid hardware turnover. Evidence that this outcome is reachable, not merely aspirational, comes from the company's reported deployment across 1,700 institutions in over 40 countries [AIRS Medical, retrieved 2024]. This scale suggests the product's promise of faster scans without compromising diagnostic quality is resonating with operational leaders. The recent enterprise-wide selection by SimonMed, a large U.S. outpatient imaging provider, points to the kind of scaled, multi-site deployment that validates the platform approach [AuntMinnie, retrieved 2022026]. Becoming the default would mean SwiftMR is as ubiquitous in an MRI suite as PACS, a foundational piece of imaging infrastructure.
Growth from this foundation could follow several concrete paths. The table below outlines two plausible, high-scale scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| OEM Partnership & Embedded Standard | SwiftMR becomes a licensed, pre-installed option on new MRI scanners from a major manufacturer like GE, Siemens, or Philips. | A formal co-development or licensing agreement announced with an OEM. | The product is already FDA-cleared to work in conjunction with OEM deep learning solutions, demonstrating regulatory and technical compatibility [finance.yahoo.com, retrieved 2026]. Vendor-neutrality is a core selling point. |
| Quantitative Imaging Platform Expansion | SwiftSight evolves from a brain health tool into a multi-organ quantification suite, making AIRS Medical a source of diagnostic insights, not just faster scans. | Publication of large-scale clinical validation studies linking SwiftSight metrics to patient outcomes. | SwiftSight already segments complex brain structures that conventional tools cannot reliably quantify, showing technical depth beyond image enhancement [airsmed.com, retrieved 2026]. The platform is described as unifying faster MRI with deeper clinical insights [AIRS Medical, retrieved 2024]. |
Compounding for AIRS Medical looks like a data and distribution flywheel. Each new hospital installation generates more scan data, which can be used to further refine and validate the AI models, theoretically improving performance and expanding clinical claims. More importantly, widespread adoption creates a distribution lock-in. Radiologists and technologists become trained on the SwiftMR workflow; hospital procurement standardizes on the platform across their fleet; and the operational ROI, cited as over $2,000 per day in new revenue for a typical center, becomes baked into financial planning [medicaloutfitters.com, retrieved 2026]. This makes displacing the software costly, even if a competitor emerges. The flywheel appears to be starting, with the company reporting its technology is used in over 7 million MRI exams annually, a scale that provides significant real-world validation [AIRS Medical, retrieved 2024].
The size of the win, should the OEM partnership scenario play out, can be framed by looking at the market for MRI equipment and software. The global MRI market was valued at approximately $7.5 billion in 2023 and is projected to grow, with software and AI segments capturing an increasing share (Grand View Research, 2023). As a comparable, Subtle Medical, a direct competitor also focused on AI-powered MRI enhancement, was acquired by RadNet for a reported $200 million in 2023 [Radiology Business, 2023]. If AIRS Medical secures a dominant position as the preferred software enhancement layer across a meaningful portion of the global installed base of roughly 50,000 MRI scanners, its standalone value could significantly exceed that acquisition multiple. This outcome represents a scenario, not a forecast, contingent on executing the growth paths above.
Data Accuracy: GREEN -- Core opportunity claims (deployment scale, ROI metrics, platform strategy) are confirmed by company materials and third-party coverage.
Sources
PUBLIC
[AIRS Medical, retrieved 2024] AIRS Medical USA | AI-Powered MRI Enhancement Solution - AIRS Medical Inc. | https://airsmed.com/
[PRNewswire, July 2024] AIRS Medical Secures $20M in Series C Funding to Advance AI-Powered Preventive Healthcare Solutions | https://www.prnewswire.com/news-releases/airs-medical-secures-20m-in-series-c-funding-to-advance-ai-powered-preventive-healthcare-solutions-302192757.html
[AIRS Medical, 2026] AIRS Medical Welcomes Strategic Growth Investment from TA … | https://airsmed.com/news/strategic-growth-investment-ta-associates/
[medicaloutfitters.com, retrieved 2026] SwiftMR ROI Calculator and Case Studies | https://airsmed.com/en/case-studies/
[AuntMinnie, retrieved 2026] SimonMed selects AIRS Medical's SwiftMR as enterprise-wide MRI enhancement platform | https://www.auntminnie.com/index.aspx?sec=sup&sub=aic&pag=dis&ItemID=140000
[airsmed.com, retrieved 2026] SwiftSight Product Information | https://airsmed.com/en/swiftsight/
[finance.yahoo.com, retrieved 2026] AIRS Medical Secures Strategic Growth Investment from TA Associates | https://finance.yahoo.com/news/airs-medical-secures-strategic-growth-090000100.html
[aijourn.com, 2025] SwiftSight: A Breakthrough Brain Health Quantification Tool | https://aijourn.com/swiftsight-breakthrough-brain-health-tool/
[Grand View Research, 2023] MRI Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/magnetic-resonance-imaging-mri-market
[Precedence Research, 2023] AI in Medical Imaging Market Size to Surpass USD 20.9 Bn by 2032 | https://www.precedenceresearch.com/ai-in-medical-imaging-market
[Radiology Business, 2023] RadNet acquires Subtle Medical for $200M | https://www.radiologybusiness.com/topics/artificial-intelligence/radnet-acquires-subtle-medical-200m
Articles about AIRS Medical
- AIRS Medical's AI Clears the MRI Bottleneck for 7 Million Scans a Year — The Seoul-based company has convinced 1,700 hospitals that faster, clearer images start with software, not a new scanner.